Muhlenkamp & Co’s Pacific Biosciences PACB Stock Holding History

Muhlenkamp & Co’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-11,125	Closed	-$41K	–	67
2015 Q3	$41K	Buy	+11,125	New	+$54.4K	0.01%	61

Other funds holding PACB

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Muhlenkamp & Co's PACB Position: Q4 2015 in Review

Muhlenkamp & Co sold out of Pacific Biosciences (PACB) in Q4 2015, closing a stake of 11,125 shares — an estimated $41K sold.

Muhlenkamp & Co first reported a position in PACB in Q3 2015 and held it in 1 quarter. The position peaked at $41K in Q3 2015. 119 funds tracked by Wall St. Rank hold PACB as of Q4 2015.

Muhlenkamp & Co reported no remaining Pacific Biosciences position as of Q4 2015 after selling out during the quarter.
Muhlenkamp & Co sold 11,125 Pacific Biosciences shares in Q4 2015, an estimated $41K.
Muhlenkamp & Co first reported a position in Pacific Biosciences in Q3 2015 and held it in 1 quarter.
Muhlenkamp & Co's Pacific Biosciences position peaked at $41K in Q3 2015.
119 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2015.

Based on Muhlenkamp & Co's 13F filing for Q4 2015, filed 10 Feb 2016.